An 8 week double blind, placebo-controlled, parallel group, fixed dosage study to evaluate the efficacy and safety of armodafinil treatment (150mg/day) as adjunctive therapy in adults with major depression associated with bipolar I disorder.

Trial Profile

An 8 week double blind, placebo-controlled, parallel group, fixed dosage study to evaluate the efficacy and safety of armodafinil treatment (150mg/day) as adjunctive therapy in adults with major depression associated with bipolar I disorder.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jul 2013

At a glance

  • Drugs Armodafinil (Primary)
  • Indications Bipolar I disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 May 2013 Results presented at the 18th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
    • 28 Jul 2011 New source identified and integrated (European Clinical Trials Database).
    • 17 Dec 2010 Actual initiation date changed from May 2007 to Jun 2007 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top